title: Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines.
authors.forename: Maeva
authors.initials: M
authors.lastname: Dufies
authors.forename: Ophelie
authors.initials: O
authors.lastname: Cassuto
authors.forename: Arnaud
authors.initials: A
authors.lastname: Jacquel
authors.forename: Guillaume
authors.initials: G
authors.lastname: Robert
authors.forename: Patrick
authors.initials: P
authors.lastname: Auberger
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D001549:Benzamides / Q000627:therapeutic use / Q000633:toxicity*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D007093:Imidazoles / Q000627:therapeutic use / Q000633:toxicity*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use / Q000633:toxicity*; D011724:Pyridazines / Q000627:therapeutic use / Q000633:toxicity*; D011743:Pyrimidines / Q000627:therapeutic use / Q000633:toxicity*
chemical_list: D001549:Benzamides; D007093:Imidazoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; D011743:Pyrimidines; C545373:ponatinib; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: BCR-ABL; T315I mutation; TKI; chronic myelogenous leukemia; dasatinib; imatinib; nilotinib; ponatinib; resistance